Progress toward valid transgenic mouse models for Alzheimer's disease

Neurobiology of Aging

Volumn 20, Issue 2, 1999, Pages 201-211

  Guénette, Suzanne Y ^a   Tanzi, Rudolph E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 2;

ALLELISM; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; GENE OVEREXPRESSION; MOUSE; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; DISEASE MODELS, ANIMAL; GLIOSIS; MEMBRANE PROTEINS; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NEURITES; NEURONS; PEPTIDE FRAGMENTS; PRESENILIN-1; TAU PROTEINS;

EID: 0032855097     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(99)00042-1     Document Type: Article

References (106)

1. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice [see comments]. Neuron 1997;19:755-9.
2. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 1991;181:265-71.
3. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition [letter] [see comments]. Nat Genet 1997;17:263-4.
4. Bardel KA, Hoeger EJ, Holtz G, Anderson JJ, Wagner SL, Borchelt DR, Sisodia SS, Lamb BT. Development of β-amyloid deposits in mutant APP and PS-1 yeast artificial chromosome transgenic mice. Soc Neurosci Abstr 1998;24:1502.
5. Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997;48:139-47.
6. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B Jr, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease [see comments]. Nat Genet 1998;19:357-60.
7. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-45.
8. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abetal-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-13.
9. Brindle N, Song Y, Rogaeva E, Premkumar S, Levesque G, Yu G, Ikeda M, Nishimura M, Paterson A, Sorbi S, Duara R, Farrer L, St George-Hyslop P. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in alzheimer disease. Hum Mol Genet 1998;7:933-5.
10. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JPGJF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc [see comments]. Science 1994;265:1464-67.
11. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice [letter]. Nature 1998;395:755-6.
12. Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 1997;6:1951-9.
13. Chapman S, Michaelson DM. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J Neurochem 1998;70:708-14.
14. Chen L, Baum L, Ng HK, Chan YS, Mak YT, Woo J, Chiu H, Pang CP. No association detected between very-low-density lipoprotein receptor (VLDL-R) and late-onset Alzheimer's disease in Hong Kong Chinese. Neurosci Lett 1998;241:33-6.
15. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [see comments]. Nat Med 1997;3:67-72.
16. Clatworthy AE, Gomez-Isla T, Rebeck GW, Wallace RB, Hyman BT. Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol 1997;54:1289-92.
17. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families [see comments]. Science 1993;261:921-3.
18. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:184-90.
19. Crawford F, Fallin D, Suo Z, Abdullah L, Gold M, Gauntlett A, Duara R, Mullan M. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett 1998;249:115-8.
20. Czech C, Delaere P, Macq AF, Reibaud M, Dreisler S, Touchet N, Schombert B, Mazadier M, Mercken L, Theisen M, Pradier L, Octave JN, Beyreuther K, Tremp G. Proteolytical processing of mutated human amyloid precursor protein in transgenic mice. Brain Res Mol Brain Res 1997;47:108-16.
21. Dai XY, Nanko S, Hattori M, Fukuda R, Nagata K, Isse K, Ueki A, Kazamatsuri H. Association of apolipoprotein E4 with sporadic Alzheimer's disease is more pronounced in early onset type. Neurosci Lett 1994;175:74-6.
22. Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, Borchelt DR, Sisodia SS, Wong PC. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron 1998;20:603-9.
23. De Strooper B, Umans L, Van Leuven F, Van Den Berghe H. Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway. J Cell Biol 1993;121:295-304.
24. DeKosky ST, Aston CE, Kamboh MI. Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. Ann N Y Acad Sci 1996;802:27-34.
25. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-3.
26. Ezquerra M, Blesa R, Tolosa E, Ballesta F, Oliva R. Alpha-antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. Neurosci Lett 1998;240:107-9.
27. Fagan AM, Murphy BA, Patel SN, Kilbridge JF, Mobley WC, Bu G, Holtzman DM. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol 1998;151:314-25.
28. Fallin D, Gauntlett AC, Scibelli P, Cai X, Duara R, Gold M, Crawford F, Mullan M. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol 1997;14:299-305.
29. Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem 1998;70:1991-7.
30. Forman MS, Cook DG, Leight S, Doms RW, Lee VM. Differential effects of the swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells. J Biol Chem 1997;272:32247-53.
31. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-7.
32. Gearing M, Mori H, Mirra SS. Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996;39:395-9.
33. Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias [In Process Citation]. Neuron 1998;21:955-8.
34. Gomez-Isla T, Hyman BT. Connections and cognitive impairment in Alzheimer's disease. In Hyman BT, Duyckaerts C, Christen Y (editors). Connections, cognition and alzheimer's disease. Heidelberg: Springer-Verlag, 1997. p. 149-66.
35. Goodman Y, Mattson MP. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 1994;128:1-12.
36. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 1995;199:1-4.
37. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Abeta40 or Abeta42(43). J Biol Chem 1995;270:7013-6.
38. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, Farrer LA, Auerbach SA, Gusella JF, Locke PA, Rosi BL, Yamaoka L, Small GW, Conneally PM, Roses AD. No genetic effect of alphal-antichymotrypsin in Alzheimer disease. Genomics 1996;33:53-6.
39. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, Farrer LA, Auerbach SA, Gusella JF, Locke PA, Rosi BL, Yamaoka L, Small GW, Conneally PM, Roses AD, Pericak-Vance M. No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. Ann N Y Acad Sci 1996;802:35-41.
40. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 1994;35:598-607.
41. Higgins LS, Rodems JM, Catalano R, Quon D, Cordell B. Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751. Proc Natl Acad Sci USA 1995;92:4402-6.
42. Ho L, Fukuchi K, Younkin SG. The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J Biol Chem 1996;271:30929-34.
43. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
44. Houlden H, Crook R, Backhovens H, Prihar G, Baker M, Hutton M, Rossor M, Martin JJ, Van Broeckhoven C, Hardy J. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. Am J Med Genet 1998;81:117-21.
45. Howland DS, Savage MJ, Huntress FA, Wallace RE, Schwartz DA, Loh T, Melloni RH Jr, DeGennaro LJ, Greenberg BD, Siman R, Swanson ME, Scott RW. Mutant and native human beta-amyloid precursor proteins in transgenic mouse brain [see comments]. Neurobiol Aging 1995;16:685-99.
46. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
47. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, ladecola C, Clark HB, Carlson G. Age related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995;15:1203-18.
48. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-9.
49. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, Takahashi H, Tsuji S, Gearing M, Mizutani T, Yamada S, Kato M, St. George-Hyslop PH, Mirra SS, Mori H. Abetal-40 but not Abetal-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997;748:250-2.
50. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (Abeta) deposition: Abeta42(43) precedes Abeta40 in Down Syndrome. Ann Neurol 1995;37:294-9.
51. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
52. Jin LW, Ninomiya H, Roch JM, Schubert D, Masliah E, Otero DA, Saitoh T. Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension. J Neurosci 1994;14:5461-70.
53. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997;94:1550-5.
54. Kamboh MI, Ferrell RE, DeKosky ST. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci Lett 1998;244:65-8.
55. Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught JL, Neve RL. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc Natl Acad Sci USA 1992;89:10857-61.
56. Kuby J. Immunology. New York: WH Freeman and Co., 1997.
57. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995;9:21-30.
58. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet 1997;6:1535-41.
59. Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, Pearson PL, Price DL, Gearhart JD. Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice. Nat Genet 1993;5:22-30.
60. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-6.
61. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogenous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16-32.
62. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 1996;2:1146-50.
63. Liao A, Nitsch RM, Greenberg SM, Finckh U, Blacker D, Albert M, Rebeck GW, Gomez-Isla T, Clatworthy A, Binetti G, Hock C, Mueller-Thomsen T, Mann U, Zuchowski K, Beisiegel U, Staehelin H, Growdon JH, Tanzi RE, Hyman BT. Genetic association of an alpha2-macroglobulin (Val1000Ile) polymorphism and Alzheimer's disease. Hum Mol Genet 1998;7:1953-6.
64. Liddell M, Williams J, Bayer A, Kaiser F, Owen M. Confirmation of association between the e4 allele of apoliprotein E and Alzheimer's disease. J Med Genet 1994;31:197-200.
65. Loring JF. Design of animal models of Alzheimer's disease with amyloid precursor protein transgenes. In Hooper N, editor, Alzheimer's disease: methods and protocols, Vol. 32: Methods in molecular medicine. Totowa, NJ: Humana Press, 1999.
66. Malherbe P, Richards JG, Martin JR, Bluethmann H, Maggio J, Huber G. Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Neurobiol Aging 1996;17:205-14.
67. Markowska AL, Grinnell D, Price DL, Borchelt DR. Age-related cognitive impairment in transgenic mice expressing an APP695 transgene with mutations linked to familial Alzheimer's disease. Soc Neurosci Abstr (1998) T-14.
68. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996;16:5795-811.
69. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993;10:243-54.
70. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998;95:12683-8.
71. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992;9:129-37.
72. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999;274:6483-92.
73. Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F. Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 1996;15:1265-74.
74. Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Portbury S, Multhaup G, Small DH, Tanzi RE, Beyreuther K, Masters CL. Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem 1998;273:5013-9.
75. Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci USA 1995;92:5341-45.
76. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res 1994;666:151-67.
77. Muramatsu T, Matsushita S, Arai H, Sasaki H, Higuchi S. Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. J Neural Transm 1996;103:1205-10.
78. Murphy GM Jr, Sullivan EV, Gallagher-Thompson D, Thompson LW, van Duijn CM, Forno LS, Ellis WG, Jagust WJ, Yesavage J, Tinklenberg JR. No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Neurology 1997;48:1313-6.
79. Nacmias B, Marcon G, Tedde A, Forleo P, Latorraca S, Piacentini S, Amaducci L, Sorbi S. Implication of alpha 1-antichymotrypsin polymorphism in familial Alzheimer's disease. Neurosci Lett 1998;244:85-8.
80. Nalbantoglu J, Tirado-Santiago G, Lahsaïni A, Poirier J, Goncalves O, Verge G, Momoli F, Weiner SA, Massicotte G, Julien J-P, Shapiro ML. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 1997;387:500-5.
81. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H, Oyanagi K, Mizusawa H, Kanazawa I, Shoji T. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995;11:207-9.
82. Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996;16:6732-41.
83. Oyama F, Sawamura N, Kobayashi K, Morishima-Kawashima M, Kuramochi T, Ito M, Tomita T, Maruyama K, Saido TC, Iwatsubo T, Capell A, Walter J, Grunberg J, Ueyama Y, Haass C, Ihara Y. Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem 1998;71:313-22.
84. Payami H, Schellenberg GD, Zareparsi S, Kaye J, Sexton GJ, Head MA, Matsuyama SS, Jarvik LF, Miller B, McManus DQ, Bird TD, Katzman R, Heston L, Norman D, Small GW. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 1997;49:512-8.
85. Peterson DA, Leppert JT, Lee KF, Gage FH. Basal forebrain neuronal loss in mice lacking neurotrophin receptor p75 [letter; comment]. Science 1997;277:837-9.
86. Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Ann Rev Genet 1998;32:461-93.
87. Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abetal-42/43 expression. Neuron 1998;20:611-7.
88. Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 1991:352:239-41.
89. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L. Isoform-specific effects of human apoliprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 1998;95:10914-9.
90. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" AB sequence. J Biol Chem 1996;271:23380-8.
91. Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, Saitoh T. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci USA 1994;91:7450-4.
92. Sberna G, Saez-Valero J, Li QX, Czech C, Beyreuther K, Masters CL, McLean CA, Small DH. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J Neurochem 1998;71:723-31.
93. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments]. Nat Med 1996;2:864-70.
94. Schubert D, Behl C. The expression of amyloid beta protein precursor protects nerve cells from beta-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res 1993;629:275-82.
95. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, Edwardson JA, Morris CM. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease [In Process Citation]. Hum Mol Genet 1998;7:937-9.
96. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S, Ryynanen M, Riekkinen P Sr. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995;187:79-82.
97. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993:90:1977-81.
98. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K-H, Mistl C, Rothacher S, Lederman B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Stauffenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997;94:13287-92.
99. Thinakaran G, Regard JB, Bouton CM, Harris CL, Price DL, Borchelt DR, Sisodia SS. Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol Dis 1998;4:438-53.
100. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau SN. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994;54:643-9.
101. Van der Zee CE, Ross GM, Riopelle RJ, Hagg T. Survival of cholinergic forebrain neurons in developing p75NGFR-deficient mice [see comments]. Science 1996;274:1729-32.
102. Wirak DO, Bayney R, Ramabhadran TV, Fracasso RP, Hart JT, Hauer PE, Hsiau P, Pekar SK, Scangos GA, Trapp BD. Deposits of amyloid beta protein in the central nervous system of transgenic mice. Science 1991;253:323-5.
103. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L. Amyloidogenic role of cytokine TGF-betal in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6.
104. Yeo TT, Chua-Couzens J, Butcher LL, Bredesen DE, Cooper JD, Valletta JS, Mobley WC, Longo FM. Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation. J Neurosci 1997;17:7594-605.
105. Yoshizawa T, Yamakawa-Kobayashi K, Hamaguchi H, Shoji S. Alpha 1-antichymotrypsin polymorphism in Japanese cases of Alzheimer's disease. J Neurol Sci 1997;152:136-9.
106. Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, St George-Hyslop PH, Fraser PE. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem 1998;273:16470-5.